ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0224

Risk Factors and Outcomes for Repeat COVID-19 Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Case-control Study
Abstract Number: 0987

Risk Factors and Predictors of Disease Activity in Rheumatoid Arthritis and Psoriatic Arthritis: Data from the Mexican Adverse Events Registry (BIOBADAMEX)
Abstract Number: 1298

Risk Factors Associated with Venous Thromboembolism in Rheumatoid Arthritis in Clinical Practice
Abstract Number: 2527

Risk Factors for Bone Loss in Systemic Lupus Erythematosus
Abstract Number: 2052

Risk Factors for Hospitalization for SARS-CoV-2 in Pediatric Patients with Rheumatic Diseases: A Systematic Review and Meta-analysis
Abstract Number: 1479

Risk Factors for Human Papillomavirus Cervical Infection and Clearance in Patients with Systemic Lupus Erythematosus: The PAPILUP Study
Abstract Number: 0680

Risk Factors for Hypogammaglobulinemia and Association with Relapse and Severe Infections in ANCA-Associated Vasculitis: A Retrospective Single-Centre Cohort Study
Abstract Number: 0564

Risk Factors for Immune Thrombocytopenia in Systemic Lupus Erythematosus and Generation of a Predictive Model to Assess Its Risk of Development
Abstract Number: 1291

Risk Factors for Major Adverse Cardiovascular Events and Malignancies in Patients with Rheumatoid Arthritis in a Real-World Setting in Japan
Abstract Number: 0272

Risk Factors for Severe Outcome in Susac Syndrome: A National Cohort Study
Abstract Number: 1455

Risk Factors of Cytomegalovirus Reactivation and Disease in Patients with Systemic Lupus Erythematosus
Abstract Number: 0115

Risk Factors of First Thrombosis in Obstetric Antiphospholipid Syndrome
Abstract Number: 1281

Risk of Cancer in Patients with Rheumatoid Arthritis Under Tocilizumab: Data from the French National Registry REGATE
Abstract Number: 0528

Risk of Cardiovascular Disease Associated with Long-term Use of NSAIDs in Ankylosing Spondylitis
Abstract Number: L11

Risk of Cardiovascular Events According to Biological Agent Exposure in Patients with Ankylosing Spondylitis: A Korean Population-based Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].